

# Expression of mRNA for IL-22 Binding Protein in the Bronchoalveolar Fluid after Inhaled Allergen Challenge in Subjects with Asthma

Alexander Behnke<sup>3</sup>, Franziska Trudzinski<sup>1</sup>, Quoc Thai Dinh<sup>2</sup> and Sebastian Fährdrich<sup>1\*</sup>

<sup>1</sup>Department of Internal Medicine V – Pulmonology, Allergology, Intensive Care Medicine, Saarland University Hospital, Homburg, Germany

<sup>2</sup>Department of Experimental Pneumology – Saarland University Hospital, Homburg, Germany

<sup>3</sup>Department of Pneumology/Intensive Care Medicine, University of Rostock, Germany

\*Corresponding author: Sebastian Fährdrich, Department of Internal Medicine V – Pulmonology, Allergology, Intensive Care Medicine, Saarland University Hospital, Homburg, Germany, Tel: +49 (0)6841 16 23601; Fax: +49 (0)6841 16 23602; E-mail: [Sebastian.fahndrich@uks.eu](mailto:Sebastian.fahndrich@uks.eu)

Received date: January 28, 2017; Accepted date: February 24, 2017; Published date: March 03, 2017

Copyright: © 2017 Behnke A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

## Abstract

**Background:** T helper (Th)17/22 cells may play a role in allergic asthma. Recent findings showed increased mRNA expression for IL-22 in peripheral blood mononuclear cells (PBMC) from patients with asthma. Thereby, the role of the natural antagonist of IL-22, IL-22 binding protein (IL-22 BP), a soluble receptor for IL-22, remains to be elucidated. In this study, we investigate the expression of mRNA for IL-22 BP in individuals with asthma.

**Methods:** We assessed the effect of allergen inhalation challenge on mRNA-expression for IL-22 and IL-22 BP, and IL-22 receptor in mononuclear cells of the bronchoalveolar fluid (BALF) from individuals with allergic asthmatic. Furthermore, *in vitro* we investigated mRNA expression for IL-22 and IL-22 BP, and IL 22 receptor after co-stimulation of peripheral blood mononuclear cells (PBMC) from individuals with asthma and normal controls with Th2 cytokines IL-4, IL-9, and GM-CSF in a time-dependent manner.

**Results:** The expression of mRNA for IL-22-BP in PBMCs from healthy controls and individuals with asthma could be found after co-stimulation with IL-4 after a minimum of 12 hours, which hold on for 96 hours. The expression of mRNA for IL-22 BP in subjects with atopic asthma was discovered in mononuclear cells of the BALF after segmental allergen inhalation challenge. Our findings suggest a possible role for IL-22 BP in allergen-induced airway responses.

**Keywords:** Asthma; Bronchoalveolar fluid; Allergen challenge

## Introduction

Asthma is a reversible airway obstruction that is characterized by hyperirritability of the airways, airway inflammation and remodeling of the airways that is associated with constriction of airway smooth muscle, hyper secretion of mucus, edema and thickening of the basement membrane underlying the airway epithelium [1].

Allergen specific T helper (Th) 2 cells play a key role by the activation and chemotactic recruitment of eosinophil granulocytes in the lung tissue, which is mediated especially by Th2 cytokines such as IL-4, IL-5, and IL-13 [2-8]. These cytokines themselves produce different mediators, that sustain airway inflammation [9,10].

Recent findings provide some evidence that another subset of T helper cells, Th22 cells, which produce IL-22, may play a role in severe asthma [8]. Previous publications reported elevated levels of IL-22 mRNA in peripheral blood mononuclear cells from individuals with atopic that correlate with the severity of asthma [11-13]. IL-22 is a cytokine belonging to the IL-10 family. It binds to a heterodimer receptor that consists of two chains: IL-22R1 and IL-10R2 chain [14,15]. Lung epithelial cells - but not mononuclear cells - express the IL-22 receptor [14,16]. Effector functions of IL-22 depend on the presence of other cytokines, e.g. IL-17A. Previous studies described inhibitory effects of IL-22 on the antigen-induced eosinophilic

inflammation in airways [17]. In a mouse model of Th2-induced lung inflammation, IL-22 was protective and reduced levels of IL-13 and IL-25, which was associated with a decline of eosinophil recruitment [17].

To gain more information about IL-22 biology in asthma, we do not only consider mRNA expression for IL-22, IL-22 receptor, we also investigated mRNA expression for IL-22-binding protein (IL-22BP), a soluble receptor for IL-22. The role of this natural antagonist is still unknown. Others demonstrate that IL-22-induced immune suppression was abolished by IL-22 BP, which was secreted by immature dendritic cells and neutralized IL-22 with higher affinity than IL-22R1 as natural antagonist of IL-22 [14]. However, the role of IL-22 BP in asthma remains to be elucidated. Therefore, we asked for the mRNA expression of IL-22BP in the bronchoalveolar fluid (BALF) of individuals with asthma after segmental allergen challenge. In a second step, we investigated, if expression of mRNA for IL-22BP in peripheral blood mononuclear cells (PBMC) is inducible by co-stimulation with Th2 cytokines.

## Materials and Methods

### Inhaled allergen challenge and determination of the PD20

We performed Inhaled allergen challenge according to Virchow et al. [19] without any changes. All of the nonsmoking allergic patients with asthma gave their written informed consent. The local ethics

committee approved the present study. Allergic asthma was diagnosed by the following criteria: Positive skin prick test result (to rye pollen, birch pollen, grass pollen, cat, or *Dermatophagoides pteronissinus/farinae*) and specific IgE. We used the specific allergen for inhaled allergen provocation. Concomitant medication: We stopped corticosteroids 14 days before inhaled/segmental allergen challenge. Patients inhaled 1 mL of normal saline from a jet nebulizer (Pari Boy;

Pari Werke, Starnberg, Germany; breathing at tidal volume, average: 25-40 breaths). We used allergen as standardized extracts from Allergopharma (Reinbeck, Germany) (including grass and cat), later from ALK-Abelló (Bornheim, Germany) (10 biological units/mL), and subsequently from HAL Allergy GmbH (Düsseldorf, Germany) (1000 allergen units/mL for rye and birch; 100 allergen units/mL for *Dermatophagoides pteronissinus*) (Tables 1 and 2).

Proband	Sex	Age [Years]	FEV1 Baseline [L]	FEV1 pred] [%]	Total-IgE [kU/l]	specific IgE [kU/ml]	Inhalation-allergen-Test	Diagnosis
1	W	24	3.8	109	52	<i>D. pteron</i> 13.8	Positive	Asthma
						<i>D. farinae</i> 16.9		
2	W	24	3.8	110	312	Birke 3.7	Positive	Asthma
						<i>D. pteron</i> 63.8		
						<i>D. farinae</i> 81.7		
3	M	35	6.3	124	116	Birke 35.2	Positive	Asthma
						Roggen 3.8		

**Table 1:** Individuals with asthma (N=3) that underwent inhaled allergen challenge for the investigation of the BALF.

Proband	Age	Sex	Allergen	FEV1 predicted	%	Total-IgE (kU/l)
A 1	23	F	Animal hair, grass pollen	97		692
A 2	23	M	Hay, grass pollen	94.6		211
A 3	22	F	Animal hair	56.8		320
A 4	19	F	Grass pollen	106		502
A 5	24	M	Dust, pollen	99		2003
A 6	33	M	Birch	97		264
Mean	24			91.7		665.3
K 1	28	M	None	n.d.		n.d.
K 2	19	W	None	n.d.		n.d.
K 3	24	M	None	n.d.		n.d.
K 4	24	M	None	n.d.		n.d.
K 5	26	M	None	n.d.		n.d.
K 6	23	W	None	n.d.		n.d.
Mean	24					

**Table 2:** Characteristics of individuals with asthma and healthy controls that donate blood for purification of PMNCs.

Patients inhaled a 1:10.000 or 1:1000 dilution of the allergen with subsequent spirometry after 10 minutes. We used the next higher allergen concentration after 10 cumulative breaths. The procedure repeated until observation of a 20% decrease in FEV1. Subsequently, we measured FEV1 at 0.5, 1, 2, 4, 6, and sometimes 8 hours after

allergen inhalation. As a criterion for a late-phase reaction we considered a second decline in FEV1 of 15% from baseline (4 to 8 hours after allergen challenge as inclusion criterion). We calculated the individual PD20 by linear interpolation of the relationship between the dose of allergen inhaled and the decline in FEV1 by 20%. For the subsequent segmental allergen challenge we used the 10-fold increased dose of allergen [18].

### Segmental allergen challenge

We performed segmental allergen provocation according to Virchow et al. without any changes [19]. Bronchoscopy was done by using an Olympus bronchoscope (Olympus, Hamburg, Germany) via the nasal or oral route. Monitoring occurred by echocardiography and pulse oximetry during and after bronchoscopy. After local anesthesia [19], 2.5 mL of saline was instilled into the lower left lobe (B8) and the lingular bronchus (B4 or B5 left) as a control. Lavage of the bronchus 8 (right) and the right middle lobe (B4 or B5) was performed with 100 mL of NaCl. Ten × PD20 of allergen diluted. B8 was lavaged 10 minutes after endoscopic allergen deposition. Repetition of bronchoscopy with lavage of segments B4 or B5 in the right and the left lung occurred after 18, 24, 42, 72, or 162 hours. The monitoring was practiced for 2 to 4 hours after bronchoscopy. Patients received supplemental oxygen and β2-agonists if needed [18].

Isolation of PBMCs occurred according to Luttmann et al. [19]. We collected 30 ml of venous blood into plastic syringes containing 0.2% EDTA from healthy subjects and individuals with asthma. All subjects gave their informed consent. PBMCs were separated on a gradient of Biocoll with a density of 1.077 g/l (Biochrom, Berlin, Germany) and resuspended in RPMI supplemented with 10% heat inactivated fetal calf serum (FCS, Gibco), 100 IU/ml penicillin, 100 µg/ml streptomycin (Seromed), 2 mM l-glutamine at a concentration of 1 × 10<sup>6</sup>/ml and cultured. Cells were counted in a Neubauer-counting chamber.

**Cell cultivation and co-incubation:** Cells were cultured on a 24-well-plate (each well with 1 ml) at 37°C (atmosphere of CO<sub>2</sub> 5%). As

positive controls we used as unspecific stimulation of the cells Phorbol-myristat-Acetat (PMA-in a concentration of  $10^{-10}$  M) (Sigma-Aldrich, Munich, Germany) and Calcium-Ionophor (Sigma-Aldrich, Munich, Germany) (concentration  $10^{-6}$  M). Co-incubation with the cytokines IL-4 (ImmunoTools, Friesoythe, Germany), IL-9 (ImmunoTools, Friesoythe, Germany), GM-CSF (ImmunoTools, Friesoythe, Germany), and IL-22 (MWG Biotech, Ebersberg, Germany) occurred in various concentrations (10 ng/ml and 100 ng/ml). The duration of the stimulation varied according to the protocol (3 h, 12 h, 24 h, 48 h, 72 h and 96 h). PBMCs were washed with PBS after stimulation/co-incubation with the cytokines. For RNA-isolation, cells were solved in TriZol-Reagenz (Sigma-Aldrich, Munich, Germany) (Lysis-Puffer) and stored at  $-80^{\circ}\text{C}$ .


**Isolation of mRNA:** MessengerRNA was prepared, using the Dynal mRNA-Direct-Kit (Dynal-Biotech, Oslo, Norway) according to the recommendations of the manufacturer (Mini-Scale-quality). Cells were solved with binding/lysis puffer. The clean Bead-mRNA-aggregate remained after washing with puffer A and B. Finally, the separation of the beads from the mRNA molecules occurred by rising temperature.

**reverse transcription-PCR (rt-PCR):** The expression of IL-22, IL-22-BP, IL-22-R1 and IL-22-R2 was assessed by rt-PCR (Thermocycler MasterCycler Gradient Eppendorf, Hamburg) in PBMCs from healthy controls and individuals with atopic asthma after co-incubation with PMA, IL-4, IL-9, GM-CSF and IL-22 in a time dependent manner. The same method was used for mRNA expression for IL-22 BP and IL-22 in mononuclear cells of the BALF after segmental allergen provocation. In this study, we used the RevertAid-Kit (MBI, Erlangen). We obtained complementary cDNA by reverse transcription with Random-Hexamer-Primer and Oligo-(dT)-Primer in addition to RNase inhibitor. The amplification of the relevant cDNA with specific primers to IL-22, IL-22-BP, IL-22-R1 and IL-22-R2 followed. As positive control, mRNA expression for housekeeping-gene  $\beta$ -actin was assessed. The following primers were used: IL-22 sense, 5'-AGC AGC CCT ATA TCA CCA ACC-3'; IL-22-antisense, 5'-GCC TTA TAT GCA GGA GGT GGT-3'; IL-22-BP-sense, 5'-TGG GAG GGC ACT TAC TGG CAA CA-3'; IL-22-BP-antisense, 5'-CTC TGT GAG CCC CTT CAT AAA CC-3'; IL-22-R1-sense, 5'-CTA CGT GTG CCG AGT GAA GA-3'; IL-22-R1-antisense, 5'-AAG CGT AGG GGT TGA AGG T-3'; IL-10-R2-sense, 5'-ACA TTC GGA GTG GGT CAA TGT-3'; IL-10-R2-antisense, 5'-TCT GCA TCT CAG GAG GTC CAA-3';  $\beta$ -actin-sense, 5'-AGC GGG AAA TCG TGC GTG-3';  $\beta$ -actin-antisense, 5'-CAG GGT ACA TGG TGG TGC-3'.

## Results

### Induction of mRNA expression for IL-22 BP and IL-22 in mononuclear cells of the BALF after segmental allergen provocation

Each of the two probes of mononuclear cells from the BALF of individuals with atopic asthma ( $n=3$ ) after segmental allergen provocation showed mRNA expression for IL-22 BP and IL-22. In contrast, the mononuclear cells of the BALF from the not provoked control bronchus segments showed mRNA expression for IL-22 but not for IL-22 BP (Figure 1).



**Figure 1:** K=Kontrolle (control – not provoked control bronchus), P=individuals with atopic asthma after segmental allergen provocation.

There was neither mRNA for IL-22 R1 from the BALF of bronchus segments after segmental allergen provocation nor mRNA from the BALF of the control segments.

### Induction of mRNA expression for IL-22 BP in PBMC after stimulation with IL-4


We found expression for mRNA of IL-22-BP in PBMCs from individuals with atopic asthma and healthy controls after incubation with IL-4 (after an incubation period of 12 hours, IL-22 BP expression hold on up to 96 hours). Unstimulated PBMCs from individuals with asthma and healthy controls did not show any expression of mRNA for IL-22 BP.

There was no expression for mRNA of IL-22-BP from PBMCs of individuals with atopic asthma and healthy controls after co-incubation with the cytokines IL-9, GM-CSF, and IL-22 (incubation period of 12 hours and 96 hours) showed in Figure 2.

We assessed no mRNA-expression of IL-22-R1 in PBMCs from individuals with asthma and healthy controls neither without stimulation nor after stimulation with PMA, IL-4, IL-9, GM-CSF and IL-22.

We found a constitutive mRNA-expression of IL-10-R2 in stimulated (PMA, IL-4, IL-9, GM-CSF, and IL-22, incubation period of 12 hours and 96 hours) and unstimulated PBMCs from individuals with asthma as well from healthy controls.

The expression of mRNA for IL-22 was continuously in all probes (stimulated PBMCs with PMA, IL-4, IL-9, GM-CSF, and IL-22 after an incubation period of 12 hours and 96 hours and unstimulated PBMCs from individuals with asthma as well from healthy controls).



## Discussion and Conclusion

We found expression for mRNA of IL-22 BP in mononuclear cells of the BALF from individuals with atopic asthma after segmental allergen inhalation challenge in our preliminary study. *In vitro*, we could induce mRNA expression for IL-22 BP in PBMCs from individuals with atopic asthma and healthy controls after co-incubation with the Th2 cytokine IL-4. In accordance with others, we found continuous mRNA expression for IL-22 – and not for the both receptor chains - in PMCs and mononuclear cells of the BALF [15,20].

Although protein expression for IL-22 BP remains to prove, our preliminary study suggests that IL-22 BP may play a role in a Th2 cytokine driven allergic inflammation as natural antagonist for IL-22.

After allergen exposure, allergen specific T helper (Th) 2 cytokines cause airway inflammation by the recruitment of additional T cells and eosinophil granulocytes in the lung tissue through secretion of a wide range of different pro inflammatory mediators that sustain allergic inflammation [6,8].

Allergic inflammation induced by allergen inhalation is associated with high levels of Th2 cytokines IL-4, IL-5, IL-13 and elevated numbers of eosinophils in the BALF [21]. We do not only found mRNA expression for IL-22 BP in contrast to controls in our *in vivo* model of a Th2 emphasized allergic inflammation, we also could

induce IL-22 BP by stimulation of PBMCs with the Th2 cytokine IL-4 *in vitro*.

Previous publications reported that the cytokine IL-22 could play a role in asthma. Serum levels of IL-22 are higher in patients with severe asthma than in patients with mild asthma and healthy controls. Moreover, plasma concentrations of IL-22 tended to increase with the severity of the disease [13].

According to observations in mouse models, IL-22 seems to have anti-inflammatory effects with regard to allergic inflammation in airways [17]. IL-22 neutralization during antigen challenge enhanced allergic lung inflammation with increased Th2 cytokines. Consistent with this, recombinant IL-22 given with allergen challenge protects mice from lung inflammation [22].

Our preliminary study put the question, if there is a quantitative relationship between protein expression of IL-22 BP, IL-22 and IL-4 as well as eosinophilia in the BALF of individuals with asthma after allergen inhalation. For this purpose, a quantitative assessment of protein expression for IL-22 BP and a correlation with the quantitative assessment of Th2-cytokines and eosinophils in the BALF after allergen provocation should be a target for further investigations in future.

The association of mRNA expression for IL-22 BP with a Th2 driven inflammation is remarkable, because IL-22 BP is the antagonist for IL-22 [22].

The results of our preliminary mRNA expression study should encourage further investigations because a probable dysregulated action of IL-22 by IL-22 BP may be a target for therapeutic interventions in asthma in future.

## References

- Kim SH, Kim BK, Lee YC (2012) Effects of Corni fructus on ovalbumin-induced airway inflammation and airway hyper-responsiveness in a mouse model of allergic asthma. *J Inflamm (Lond)* 9: 9.
- Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, et al. (2001) Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. *Clin Exp Immunol* 125: 177-83.
- Lee YC, Lee KH, Lee HB, Rhee YK (2001) Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. *J Asthma* 38: 665-71.
- Stirling RG, Chung KF (2000) Future treatments of allergic diseases and asthma. *Br Med Bull* 56: 1037-53.
- Zhao J, Lloyd CM, Noble A (2013) Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling. *Mucosal Immunol* 6: 335-46.
- Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, et al. (2000) Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. *J Immunol* 165: 108-13.
- Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM (2008) Global strategy for asthma management and prevention: GINA executive summary. *Eur Respir J* 31: 143-78.
- Taube C, Tertilt C, Gyöveszi G, Dehzad N, Kreymborg K, et al. (2011) IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. *PLoS One* 6: e21799.
- Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. *Nat Med* 13: 139-45.
- Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. *Nature* 453: 1051-7.

11. Farfariello V, Amantini C, Nabissi M, Morelli MB, Aperio C, et al. (2011) IL-22 mRNA in peripheral blood mononuclear cells from allergic rhinitic and asthmatic pediatric patients. *Pediatr Allergy Immunol* 22: 419-23.
12. Zhu J, Cao Y, Li K, Wang Z, Zuo P, et al. (2011) Increased expression of aryl hydrocarbon receptor and interleukin 22 in patients with allergic asthma. *Asian Pac J Allergy Immunol* 29: 266-72.
13. Zhao Y, Yang J, Gao YD, Guo W (2010) Th17 immunity in patients with allergic asthma. *Int Arch Allergy Immunol* 151: 297-307.
14. Sabat R, Ouyang W, Wolk K (2014) Therapeutic opportunities of the IL-22-IL-22R1 system. *Nat Rev Drug Discov* 13: 21-38.
15. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, et al. (2001) Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. *J Biol Chem* 276: 2725-32.
16. Pociask DA, Scheller EV, Mandalapu S, McHugh KJ, Enelow RI, et al. (2013) IL-22 is essential for lung epithelial repair following influenza infection. *Am J Pathol* 182: 1286-96.
17. Takahashi K, Hirose K, Kawashima S, Niwa Y, Wakashin H, et al. (2011) IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation. *J Allergy Clin Immunol* 128: 1067-1076.
18. Julius P, Grosse-Thie C, Kuepper M, Bratke K, Virchow JC (2010) sCD14 in bronchoalveolar lavage 18, 42 and 162 hours after segmental allergen provocation. *Scand J Immunol* 71: 304-11.
19. Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow JC, et al. (1996) Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. *J Immunol* 157: 1678-83.
20. Savan R, McFarland AP, Reynolds DA, Feigenbaum L, Ramakrishnan K, et al. (2011) A novel role for IL-22R1 as a driver of inflammation. *Blood* 117: 575-84.
21. Virchow JC, Walker C, Hafner D, Kortsik C, Werner P, et al. (1995) T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. *Am J Respir Crit Care Med* 151: 960-8.
22. Besnard AG, Sabat R, Dumoutier L, Renaud JC, Willart M, et al. (2011) Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. *Am J Respir Crit Care Med* 183: 1153-63.